Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MEHRAN MOUSSAVIAN

Allopathic & Osteopathic Physicians Internal Medicine Interventional Cardiology

NPI
1689788234
CMS profile
349364
Location
CHULA VISTA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$29,318.44

214 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 214 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MEHRAN MOUSSAVIAN

NPI 1689788234 · CMS profile ID 349364

Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology

CHULA VISTA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 214 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1689788234?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MEHRAN MOUSSAVIAN, NPI 1689788234, CMS profile ID 349364. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 214 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1689788234?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MEHRAN MOUSSAVIAN, NPI 1689788234, CMS profile ID 349364. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 214 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1689788234?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MEHRAN MOUSSAVIAN, NPI 1689788234, CMS profile ID 349364, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 214 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1689788234?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

214 matching records · $29,318.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 214 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 214.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Actelion Pharmaceuticals US, Inc. $16.0610/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788568489 CMS
Amgen Inc. $14.0310/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825607063 CMS
Impulse Dynamics (USA) Inc. $176.2309/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843141685 CMS
BOSTON SCIENTIFIC CORPORATION $6.6209/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777771259 CMS
Janssen Pharmaceuticals, Inc $13.9609/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788568455 CMS
BIOTRONIK INC. $8.6309/27/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843840731 CMS
BOSTON SCIENTIFIC CORPORATION $13.7509/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777771261 CMS
Janssen Pharmaceuticals, Inc $114.6109/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788568443 CMS
PFIZER INC. $17.6909/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832834887 CMS
Medtronic, Inc. $58.8309/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827262285 CMS
Abbott Laboratories $8.4609/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833676715 CMS
Abbott Laboratories $4.5909/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833676719 CMS
Janssen Pharmaceuticals, Inc $20.1309/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788568451 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.6009/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763685074 CMS
Edwards Lifesciences Corporation $144.6209/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841851351 CMS
PFIZER INC. $14.5909/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832885431 CMS
BIOTRONIK INC. $37.3709/12/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843840795 CMS
Abbott Laboratories $40.4609/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833676709 CMS
Abbott Laboratories $9.7209/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833676711 CMS
Actelion Pharmaceuticals US, Inc. $4.5609/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788568491 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $27.3409/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768779592 CMS
Esperion Therapeutics, Inc. $19.5509/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838359011 CMS
SANOFI-AVENTIS U.S. LLC $17.8309/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843522799 CMS
Abbott Laboratories $17.1708/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833676705 CMS
BOSTON SCIENTIFIC CORPORATION $30.6408/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777771255 CMS
Abbott Laboratories $136.5808/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833676699 CMS
Abbott Laboratories $14.6208/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833676703 CMS
BOSTON SCIENTIFIC CORPORATION $128.4008/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777771257 CMS
Bayer HealthCare Pharmaceuticals Inc. $24.9608/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789188697 CMS
Actelion Pharmaceuticals US, Inc. $4.8808/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788568493 CMS
Abbott Laboratories $127.2108/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833676695 CMS
CORDIS US CORP. $19.1208/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809244523 CMS
AstraZeneca Pharmaceuticals LP $17.7908/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829927647 CMS
Abbott Laboratories $29.9308/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833676693 CMS
Esperion Therapeutics, Inc. $17.5208/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838359007 CMS
ATRICURE, INC. $16.3308/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851070337 CMS
AstraZeneca Pharmaceuticals LP $14.9208/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829912405 CMS
BOSTON SCIENTIFIC CORPORATION $19.5008/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777771253 CMS
Medtronic, Inc. $5.3508/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827262279 CMS
BIOTRONIK INC. $34.0008/11/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843840791 CMS
Janssen Pharmaceuticals, Inc $3,465.0008/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788568421 CMS
Janssen Pharmaceuticals, Inc $6.4708/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788568459 CMS
PFIZER INC. $22.8608/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832783721 CMS
Medtronic, Inc. $31.5008/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827262277 CMS
Abbott Laboratories $8.8508/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833676681 CMS
Abbott Laboratories $35.5308/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833676685 CMS
Abbott Laboratories $4.6007/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833676677 CMS
Abbott Laboratories $24.9607/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833676689 CMS
AstraZeneca Pharmaceuticals LP $13.7507/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829539863 CMS
BOSTON SCIENTIFIC CORPORATION $120.2307/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777556493 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $57,538.56 231
PY2020 $10,361.83 185
PY2021 $29,318.44 214
PY2022 $16,172.80 123
PY2023 $5,370.48 98
PY2024 $18,903.96 52
PY2025 $10,932.81 49

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $362,340.00 24
PY2024 Principal investigator $639,464.62 25
PY2023 Principal investigator $161,375.37 14
PY2022 Principal investigator $207,507.84 13
PY2021 Principal investigator $32,594.20 21
PY2020 Principal investigator $2,974.50 13
PY2019 Principal investigator $4,485.00 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $16,573.00 12/12/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175169228
Principal investigator 1 Boston Scientific Corporation $16,539.10 12/09/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571873
Principal investigator 1 Boston Scientific Corporation $19,103.80 11/25/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571871
Principal investigator 1 Janssen Research & Development, LLC $23,925.00 11/19/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175169134
Principal investigator 1 Janssen Research & Development, LLC $23,333.00 11/07/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175169167
Principal investigator 1 Janssen Research & Development, LLC $950.00 11/03/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175169271
Principal investigator 1 Boston Scientific Corporation $10,803.60 10/28/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571869
Principal investigator 1 Janssen Research & Development, LLC $15,332.00 09/19/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175168934
Principal investigator 1 Boston Scientific Corporation $3,050.80 09/16/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571867
Principal investigator 1 Boston Scientific Corporation $300.00 08/26/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571865
Principal investigator 1 Janssen Research & Development, LLC $22,119.00 08/25/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175168926
Principal investigator 1 Janssen Research & Development, LLC $16,768.00 07/23/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175168949
Principal investigator 1 Janssen Research & Development, LLC $4,506.00 06/23/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175169159
Principal investigator 1 Janssen Research & Development, LLC $18,410.00 06/20/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175169176
Principal investigator 1 Boston Scientific Corporation $650.00 05/27/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571863
Principal investigator 1 Janssen Research & Development, LLC $24,533.00 05/21/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175168921
Principal investigator 1 Janssen Research & Development, LLC $22,501.00 04/23/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175169119
Principal investigator 1 Boston Scientific Corporation $2,323.10 04/08/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571861
Principal investigator 1 Janssen Research & Development, LLC $17,383.00 03/21/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175169061
Principal investigator 1 Boston Scientific Corporation $14,908.20 03/11/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571859
Principal investigator 1 Janssen Research & Development, LLC $29,783.00 02/19/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175168913
Principal investigator 1 Boston Scientific Corporation $11,636.50 02/11/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571857
Principal investigator 1 Janssen Research & Development, LLC $40,006.00 01/22/2025 Non-covered Recipient Entity
Crdvsclr Inst Of San Diego
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175168982
Principal investigator 1 Boston Scientific Corporation $6,902.90 01/14/2025 Non-covered Recipient Entity
CARDIOVASCULAR INSTITUTE OF SAN DIEGO
CHAMPION-AF No dispute reported 06/30/2026 1207571855